# Effects of Dexmedetomidine/Lidocaine/Intrathecal Morphine on Cancer Metastasis Biomarker After Colorectal Surgery

> **NCT05742438** · NA · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 114 (actual)

## Conditions studied

- Colorectal Cancer
- Anesthesia
- Cancer Metastatic
- Inflammation

## Interventions

- **DRUG:** Lidocaine IV
- **DRUG:** Dexmedetomidine IV
- **DRUG:** intrathecal morphine

## Key facts

- **NCT ID:** NCT05742438
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-12
- **Primary completion:** 2023-07-05
- **Final completion:** 2023-08-05
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2025-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05742438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05742438, "Effects of Dexmedetomidine/Lidocaine/Intrathecal Morphine on Cancer Metastasis Biomarker After Colorectal Surgery". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT05742438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*